Key Points
There is heterogeneity in the clinical, laboratory, and genetic bases of HX.
Alterations in PIEZO1 channel kinetics, response to osmotic stress, and membrane trafficking may contribute to channel dysfunction in HX.
Abstract
Mutations in PIEZO1 are the primary cause of hereditary xerocytosis, a clinically heterogeneous, dominantly inherited disorder of erythrocyte dehydration. We used next-generation sequencing–based techniques to identify PIEZO1 mutations in individuals from 9 kindreds referred with suspected hereditary xerocytosis (HX) and/or undiagnosed congenital hemolytic anemia. Mutations were primarily found in the highly conserved, COOH-terminal pore-region domain. Several mutations were novel and demonstrated ethnic specificity. We characterized these mutations using genomic-, bioinformatic-, cell biology–, and physiology-based functional assays. For these studies, we created a novel, cell-based in vivo system for study of wild-type and variant PIEZO1 membrane protein expression, trafficking, and electrophysiology in a rigorous manner. Previous reports have indicated HX-associated PIEZO1 variants exhibit a partial gain-of-function phenotype with generation of mechanically activated currents that inactivate more slowly than wild type, indicating that increased cation permeability may lead to dehydration of PIEZO1-mutant HX erythrocytes. In addition to delayed channel inactivation, we found additional alterations in mutant PIEZO1 channel kinetics, differences in response to osmotic stress, and altered membrane protein trafficking, predicting variant alleles that worsen or ameliorate erythrocyte hydration. These results extend the genetic heterogeneity observed in HX and indicate that various pathophysiologic mechanisms contribute to the HX phenotype.
Introduction
The hereditary xerocytosis (HX) syndromes are a group of dominantly inherited disorders of erythrocyte dehydration.1 HX erythrocytes exhibit decreased total cation and potassium content not accompanied by a proportional net gain of sodium and water. HX patients typically exhibit mild to moderate compensated hemolytic anemia, with variable complications including hydrops fetalis, hemolytic and aplastic episodes, thromboses, gallstones, and propensity for iron overload as an adult.2,3 Laboratory findings include increased mean corpuscular hemoglobin concentration (MCHC), decreased osmotic fragility, and a characteristic pattern on osmotic gradient ektacytometry,4 all reflecting cellular dehydration.5
Most cases of HX are associated with mutations in PIEZO1, a pore-forming channel that mediates mechanotransduction in mammalian cells, indicating that PIEZO1 plays an important role in maintaining erythrocyte volume homeostasis.2,6-10 Most, but not all, HX-associated PIEZO1 variants have been shown to exhibit a partial gain-of-function phenotype with generation of mechanically activated (MA) currents that inactivate more slowly than wild type in cell model systems.2,6,8,11 This indicates that increased cation permeability may lead to dehydration of PIEZO1-mutant HX erythrocytes.
We studied patients from 9 kindreds referred with suspected HX or undiagnosed congenital hemolytic anemia. After identifying mutations in the PIEZO1 gene, we characterized the mutations in a series of assays, including a novel, cell-based in vivo system we created for study of PIEZO1 membrane protein expression, trafficking, and electrophysiology in a rigorous manner. We identified a number of physiologic and other pathologic abnormalities associated with mutant channels. Variant alleles were identified that are predicted to worsen or ameliorate erythrocyte hydration and influence clinical severity. These results further demonstrate the genetic variability in HX and indicate that mechanisms of channel dysfunction in addition to delayed inactivation contribute to the HX phenotype.
Methods
Patients
Patients were referred with suspected HX and/or undiagnosed congenital hemolytic anemia.
All studies were approved by an institutional review board. Written informed consent was obtained from the patients or their parents.
Whole-exome sequencing and targeted capture
A cell-based model system for study of PIEZO1
Wild-type or mutant doxycycline-inducible, PIEZO1-expressing HEK293 cell lines were created using the Flp-In T-Rex system. Stable, single-site integration was verified by Southern blot, messenger RNA (mRNA) expression was validated by quantitative reverse transcription–polymerase chain reaction (RT-PCR), and protein expression was validated by western blot.
Physiologic studies
MA currents were measured in induced and uninduced HEK293 cells expressing wild-type or mutant PIEZO1 and mock-transfected cells. Force was applied to the cell surface by a glass probe mounted on a piezoelectric-driven actuator (Physik Instrumente) in a series of 150-millisecond mechanical steps, in 1-μm increments, while monitoring transmembrane currents at −80 mV in the whole-cell mode as described.14,15 MA inward currents, apparent threshold of mechanical activation, and time constant of inactivation, obtained by fitting the inactivating component of the mechanocurrent to the monoexponential equation, were monitored. Additional details are provided in supplemental Methods.
Osmotic studies
MA currents measured in the whole-cell mode in induced and uninduced HEK293 cells expressing wild-type or mutant PIEZO1 and mock-transfected cells and membrane stretch were assessed as in the previous section after hypotonic stress, achieved via perfusion of the cells with extracellular media of osmolality from 300 mOsm (isotonic) to 200 mOsm (hypotonic) for 5 minutes then back to 300 mOsm.16,17
Immunofluorescence and confocal microscopy
For immunofluorescence (IF), cells grown on glass cover slips were fixed with paraformaldehyde, washed, and a series of permeabilization, blocking, and washing steps performed, including incubation to primary antibody and fluorescently conjugated antibodies.17 Additional details are provided in supplemental Methods. Samples were examined by confocal microscopy using a Zeiss laser confocal LSM 710 NLO microscope.
Quantitative fluorescent western blotting
Ghosts were prepared from mature erythrocytes of HX patients, denatured, electrophoresed, then transferred to low-fluorescence polyvinylidene fluoride membranes. These were hybridized to anti-PIEZO1, anti-α-spectrin (control), and anti-actin (control) antibodies. Gels were imaged and data quantified. Additional details are provided in supplemental Methods.
Results
Patients
We studied patients from 9 kindreds with suspected HX (Table 1). The predominant clinical and laboratory findings were splenomegaly and hemolytic anemia with reticulocytosis (Table 1). In utero manifestations were observed in 3 kindreds. One HX mother who suffered from nonimmune hydrops fetalis (NIHF) as a fetus subsequently carried an affected fetus who also suffered from NIHF. Several patients required blood transfusion at some time during their life. Iron overload, found in 3 patients, was severe enough to require chelation in 2. Of the 3, only 1 patient (number 4; Table 1) had a significant history of transfusion. One patient (number 9) died suddenly at age 25 years; autopsy revealed cardiac iron overload.
Patient . | Sex . | Inheritance . | NIHF . | Perinatal anemia . | Any transfusion . | Enlarged spleen . | Splenectomy/ cholecystectomy . | Hb, g/dL . | MCV, fL . | MCH, pg . | MCHC, g/dL . | Retic count, % . | T bili, mg/dL . | OF . | Ekta-cytometry . | RBC electrolytes . | Ferritin/ chelation . | Mutation . |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | Unknown | No | No | No | Yes | No/yes | 10 | 29 | 35.6 | 34.8 | 2.8 | 1.9 | Nl | No | ND | 1087/yes | R1943Q |
2 | F | Unknown | No | No | No | No | No/no | 13.9 | 86 | NR | 38.3 | 10 | 5.2 | Nl | Yes | Na 56, K 208 | NR | R2088G |
3 | M | De novo | Yes | No | Yes | Yes | No/yes | 9.9 | 108 | 36 | ND | 6.4 | 2.2 | ND | No | Na 16, K 81 | 295 | R2488Q |
4 | F | AD* | No | No | Yes | Yes | No/no | 9.3 | 79.7 | 28.5 | 35.7 | 3.2 | 3.8 | Nl | Yes | ND | 1240/yes | R2302H |
5 | F | AD | NR | NR | Yes | Yes | Yes/yes | 10 | 106 | 37.6 | 36.4 | 25 | NR | Dec | No | Na 18.6, K 59.1 | NR | K1877del |
6 | F | Unknown | Yes | Yes | Yes | Yes | No/no | 12.5 | 95.4 | 35.8 | 37.5 | 11.8 | 1.3 | Both | No | ND | NR | E2496ELE |
7 | M | AD | No | No | No | Yes | No/no | 10.6 | 98.3 | 31.8 | 32.3 | 9.6 | NR | No | No | ND | 126 | E2496ELE |
8 | F | AD | Yes | Yes | Yes | Yes | Yes/yes | 10 | 115 | 39.5 | 34.8 | 4.7 | 2.5 | Dec | Yes | Na 48, K 82 | 188 | E2496ELE |
9 | F | Unknown | No | No | Yes | Yes | Yes/yes | 9.1 | 125 | 44 | 35 | 8 | 2.4 | No | Na 9.3, K95.1 | 500 | E2496ELE |
Patient . | Sex . | Inheritance . | NIHF . | Perinatal anemia . | Any transfusion . | Enlarged spleen . | Splenectomy/ cholecystectomy . | Hb, g/dL . | MCV, fL . | MCH, pg . | MCHC, g/dL . | Retic count, % . | T bili, mg/dL . | OF . | Ekta-cytometry . | RBC electrolytes . | Ferritin/ chelation . | Mutation . |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | Unknown | No | No | No | Yes | No/yes | 10 | 29 | 35.6 | 34.8 | 2.8 | 1.9 | Nl | No | ND | 1087/yes | R1943Q |
2 | F | Unknown | No | No | No | No | No/no | 13.9 | 86 | NR | 38.3 | 10 | 5.2 | Nl | Yes | Na 56, K 208 | NR | R2088G |
3 | M | De novo | Yes | No | Yes | Yes | No/yes | 9.9 | 108 | 36 | ND | 6.4 | 2.2 | ND | No | Na 16, K 81 | 295 | R2488Q |
4 | F | AD* | No | No | Yes | Yes | No/no | 9.3 | 79.7 | 28.5 | 35.7 | 3.2 | 3.8 | Nl | Yes | ND | 1240/yes | R2302H |
5 | F | AD | NR | NR | Yes | Yes | Yes/yes | 10 | 106 | 37.6 | 36.4 | 25 | NR | Dec | No | Na 18.6, K 59.1 | NR | K1877del |
6 | F | Unknown | Yes | Yes | Yes | Yes | No/no | 12.5 | 95.4 | 35.8 | 37.5 | 11.8 | 1.3 | Both | No | ND | NR | E2496ELE |
7 | M | AD | No | No | No | Yes | No/no | 10.6 | 98.3 | 31.8 | 32.3 | 9.6 | NR | No | No | ND | 126 | E2496ELE |
8 | F | AD | Yes | Yes | Yes | Yes | Yes/yes | 10 | 115 | 39.5 | 34.8 | 4.7 | 2.5 | Dec | Yes | Na 48, K 82 | 188 | E2496ELE |
9 | F | Unknown | No | No | Yes | Yes | Yes/yes | 9.1 | 125 | 44 | 35 | 8 | 2.4 | No | Na 9.3, K95.1 | 500 | E2496ELE |
AD, autosomal dominant; Dec, decreased; F, female; Hb, hemoglobin; M, male; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; ND, not done; NI, normal; NIHF, nonimmune hydrops fetalis; NR, not reported; OF, osmotic fragility; RBC, red blood cell; Retic, reticulocyte; T bili, total bilirubin.
Patient with coinherited β-globin variant. See “Results” for details.
Targeted capture, exome sequencing, and variant identification
WES or targeted capture identified 6 missense or indel mutations of the PIEZO1 gene in probands from all 9 kindreds (Table 2). At least 3 mutation prediction algorithms predicted that the 4 missense mutations were deleterious for protein function, and all 4 had highly significant combined annotation-dependent depletion (CADD) Phred scores ≥15, with 2 over 30 (Table 2), predicting pathogenic variants.18 Three of the 6 variants are novel and are not present in the 1000 Genomes, Exome Variant Server, or Exome Aggregation Consortium (ExAC) databases. The fourth variant, p.Leu2495_Glu2496dup (also known as E2496ELE), which we found in 4 kindreds, although not in the 1000 Genomes, Exome Variant Server, or ExAC databases, has been found in over a dozen unrelated HX kindreds.8,19 Patient 3, who previously was described to have a deleterious mutation in the Gardos channel, KCNN4, was found to have a homozygous, in-frame deletion in PIEZO1 (Table 2). No other mutations were detected in KCNN4 or SLC4A1 in any of the patients. The presence of each mutation was confirmed by Sanger sequencing (not shown).
Mutation . | Type . | Location . | 1000G . | ExAc . | SIFT . | LRT . | Mutation taster . | CADD Phred . |
---|---|---|---|---|---|---|---|---|
NM_001142864:c.G5828A:p.R1943Q | Missense | Exon 41 | 0.00739 | 0.0025 | 0.57 | 0.096 | 1 | 15.18 |
NM_001142864:c.C6262G:p.R2088G | Missense | Exon 43 | 0 | 0 | 0.18 | 0 | 1 | 32 |
NM_001142864:c.G7463A:p.R2488Q | Missense | Exon 51 | 0 | 4.81E-05 | 0.02 | 0 | 1 | 35 |
NM_001142864:c.G6905A:p.R2302H | Missense | Exon 47 | 0 | 0.0003 | 0.37 | 0 | 1 | 28 |
NM_001142864:c.5632_5634del:p.1878_1878del | Deletion | Exon 39 | 0.21 | 0.35 | NA | NA | NA | NA |
NM_001142864:c.7479_7484dup:p.L2495_E2496dup | Insertion | Exon 51 | 0 | 0 | NA | NA | NA | NA |
Mutation . | Type . | Location . | 1000G . | ExAc . | SIFT . | LRT . | Mutation taster . | CADD Phred . |
---|---|---|---|---|---|---|---|---|
NM_001142864:c.G5828A:p.R1943Q | Missense | Exon 41 | 0.00739 | 0.0025 | 0.57 | 0.096 | 1 | 15.18 |
NM_001142864:c.C6262G:p.R2088G | Missense | Exon 43 | 0 | 0 | 0.18 | 0 | 1 | 32 |
NM_001142864:c.G7463A:p.R2488Q | Missense | Exon 51 | 0 | 4.81E-05 | 0.02 | 0 | 1 | 35 |
NM_001142864:c.G6905A:p.R2302H | Missense | Exon 47 | 0 | 0.0003 | 0.37 | 0 | 1 | 28 |
NM_001142864:c.5632_5634del:p.1878_1878del | Deletion | Exon 39 | 0.21 | 0.35 | NA | NA | NA | NA |
NM_001142864:c.7479_7484dup:p.L2495_E2496dup | Insertion | Exon 51 | 0 | 0 | NA | NA | NA | NA |
SIFT, LRT, Mutation Taster, and CADD scores are from predicted mutation effect scores obtained from the Annovar database (http://annovar.openbioinformatics.org/en/latest/). Scores of 0 are predicted to be damaging by the SIFT and LRT algorithms whereas scores of 1 are predicted to be tolerated. The scale is inverted for the Mutation Taster algorithm.
1000G, Allele frequency in the Thousand Genomes database (http://www.internationalgenome.org/); CADD, combined annotation-dependent depletion; ExAc, ExAc Browser database (http://exac.broadinstitute.org/); LRT, likelihood ratio test; NA, not applicable; SIFT, sorting intolerant from tolerant.
Based on computer modeling, 4 of these mutations were located primarily in the COOH terminus, the region that dictates pore properties of PIEZO1 (Figure 1A).20 Recently, cryoelectron microscopy of a region of mouse Piezo1 at a resolution of 4.8 Å demonstrated that Piezo1 forms a trimeric propeller-like structure, with the extracellular domains resembling 3 peripheral blades and a central cap, with a central region that encloses a potential ion-conducting pore.21 It was suggested that force-induced motion of the peripheral blades or peripheral helices led to conformational changes and channel gating. Only 4 of our mutants were included in the reported structure: R2088G, R2302H, R2488Q, and E2496ELE. Notably, R2488Q is at the top of the cap of the predicted pore, and E2496ELE is at the junction of the α2 and α3 intracellular COOH-terminal domains, a region predicted to participate in formation of the pore module.21,22 As expected for residues in this functional COOH-terminal region of PIEZO1,23 these 4 amino acids are highly conserved across species (Figure 1B).
A cell-based model system for study of PIEZO1
To study mechanisms of mutant PIEZO1 dysfunction, we created an in vivo system for study of wild-type and mutant PIEZO1 in functional, cell-based assays. We used the Flp-In T-Rex system to generate stable mammalian HEK293 cell lines with doxycycline-inducible expression of human PIEZO1. This system allows expression of PIEZO1 in stably-transfected, single-copy HEK293 cells with a uniform integration site, allowing rigorous comparison of variant proteins with wild type. Adding rationale to development of this model, a previous study of the function of the PIEZO1 M2225R variant in transiently transfected HEK293 cells was confounded by changes due to variations introduced by transient transfections.8 We have used this system to demonstrate critical differences in cell lines expressing KCl cotransporters with alterations in a single amino acid.17 For wild type and each mutant, we developed 2 functional HEK293 cell PIEZO1 models, with or without a COOH-terminal 3X FLAG tag. HEK293 cells have been shown to be an excellent model for study of PIEZO1 function.14,15 PIEZO1 has been shown to be fully functional when a COOH-terminal tag is added,14,15 which we have validated (see next section and supplemental Data). The tag allows us to perform trafficking and IF microscopy–based assays. As positive controls, we used lines expressing the original HX-associated PIEZO1 mutations, M2225R and R2456H, which have been shown to demonstrate a delayed inactivation phenotype.8,11
We first examined our cell model systems using wild-type PIEZO1 with or without a COOH-terminal 3X FLAG tag. We demonstrated single-copy, single-genomic integration site by Southern blot (not shown), PIEZO1 mRNA expression by quantitative RT-PCR, and protein expression by western blot (supplemental Figure 1), as well as physiologic studies (see next section). Time-course experiments demonstrated significant PIEZO1 protein expression at 16 hours postinduction that persisted up to 96 hours postinduction (Figure 2A). The time frame between 24 and 48 hours postinduction was used for all experiments unless otherwise indicated. IF studies localized PIEZO1 expression to the cell membrane (Figure 2B). We then generated PIEZO1-mutant cell lines with or without FLAG tags and validated expression using comparative analyses (supplemental Figures 1 and 2). No lower-molecular-weight degradation products were detected in wild-type or mutant samples. The HX-associated mutations did not result in a significant decrease in the level of PIEZO1 expressed in HEK293 cells, suggesting the mutations did not cause a significant decrease in protein synthesis or stability.
Physiologic analyses
We measured MA currents in the whole-cell mode in induced and uninduced HEK293 cells expressing wild-type or mutant PIEZO1. MA currents were recorded after applying mechanical force on the cell surface using a glass probe, increasing in 1-μm increments of indentation, while monitoring transmembrane currents at constant voltage. After induction, cells expressing wild-type PIEZO1 with or without a FLAG tag demonstrated a rapid transient increase in current after stimulation, related to the depth of the indenting probe, as previously described (supplemental Figure 3).8 Uninduced control cells produced no MA current.
Whole-cell currents were then recorded in uninduced and induced mutant PIEZO1-expressing HEK293 cell lines. All induced wild-type and mutant MA inactivation currents could be fitted with a monoexponential function. Two mutants, R1943Q and E2496ELE, demonstrated an increase in the inactivation time constant, as did 2 previously characterized HX mutants, M2225R and R2456H, included as controls, compared with wild type (Figure 3; Table 3).2,6,8,11 This is the typical pattern that has been described with HX-associated PIEZO1 missense mutations.8 These mutants are defined as gain of function, as they prolong channel activity in response to a given mechanical stimulus. The other mutants did not demonstrate a statistically significant increase in inactivation time constant (τ, milliseconds) except for the K1877del mutant which displayed lower τ, indicating faster closing of channel (see next paragraph).
Mutation . | Inactivation kinetics . | Osmotic phenotype . | Trafficking defect . | ||||
---|---|---|---|---|---|---|---|
N . | Threshold, µm . | Inactivation time constant, Τ (ms) . | n . | Fold of amplitude increase relative to osmotic . | Comments . | ||
WT | 41 | 5.3 ± 0.2 | 6.1 ± 0.2 | 8 | 19.1 ± 0.2*** | Increase in peak current | None |
M2225R | 10 | 5.0 ± 0.2 | 11.0 ± 0.9* | 4 | 14.2 ± 0.2*** | Like WT | None |
R2456H | 12 | 5.0 ± 0.3 | 17.4 ± 1.0*** | 0 | No data | No data | None |
R1943Q | 30 | 5.1 ± 0.2 | 12.6 ± 1.1*** | 0 | No data | No data | None |
R2088G | 13 | 3.8 ± 0.3*** | 6.8 ± 0.5 | 4 | 12.1 ± 0.5*** | Like WT | Colocalization with ER and Golgi |
R2488Q | 23 | 3.9 ± 0.2*** | 6.9 ± 0.5 | 8 | 4.2 ± 0.1* | Blunted response | Colocalization with ER and Golgi |
R2302H | 27 | 4.1 ± 0.2*** | 5.8 ± 0.2 | 6 | 0.3 ± 0.1 | No response | Colocalization with ER and Golgi |
K1877del | 20 | 4.9 ± 0.2 | 5.3 ± 0.2* | 6 | 3.2 ± 0.1* | Blunted response | None |
E2496ELE | 30 | 4.7 ± 0.2 | 9.9 ± 0.5*** | 4 | 0.9 ± 0.1 | No response | None |
Mutation . | Inactivation kinetics . | Osmotic phenotype . | Trafficking defect . | ||||
---|---|---|---|---|---|---|---|
N . | Threshold, µm . | Inactivation time constant, Τ (ms) . | n . | Fold of amplitude increase relative to osmotic . | Comments . | ||
WT | 41 | 5.3 ± 0.2 | 6.1 ± 0.2 | 8 | 19.1 ± 0.2*** | Increase in peak current | None |
M2225R | 10 | 5.0 ± 0.2 | 11.0 ± 0.9* | 4 | 14.2 ± 0.2*** | Like WT | None |
R2456H | 12 | 5.0 ± 0.3 | 17.4 ± 1.0*** | 0 | No data | No data | None |
R1943Q | 30 | 5.1 ± 0.2 | 12.6 ± 1.1*** | 0 | No data | No data | None |
R2088G | 13 | 3.8 ± 0.3*** | 6.8 ± 0.5 | 4 | 12.1 ± 0.5*** | Like WT | Colocalization with ER and Golgi |
R2488Q | 23 | 3.9 ± 0.2*** | 6.9 ± 0.5 | 8 | 4.2 ± 0.1* | Blunted response | Colocalization with ER and Golgi |
R2302H | 27 | 4.1 ± 0.2*** | 5.8 ± 0.2 | 6 | 0.3 ± 0.1 | No response | Colocalization with ER and Golgi |
K1877del | 20 | 4.9 ± 0.2 | 5.3 ± 0.2* | 6 | 3.2 ± 0.1* | Blunted response | None |
E2496ELE | 30 | 4.7 ± 0.2 | 9.9 ± 0.5*** | 4 | 0.9 ± 0.1 | No response | None |
Values are mean ± standard error of the mean unless otherwise indicated.
ER, endoplasmic reticulum; n, number of experiments; N, number of tested cells; WT, wild type.
P < 0.05; ***P < 0.001 (Student t test).
Sensitivity of a channel to mechanical stimulation can be estimated by the minimal indentation measuring the apparent activation threshold for each cell. This can be calculated by establishing the minimal indentation, after cell contact is made, required to activate the channel. We observed differences in threshold for 3 mutants, R2088G, R2302H, and R2488Q (Figure 3C).
Other abnormalities in channel properties were observed. The K1877del mutant exhibited both faster channel-inactivation kinetics compared with wild type (control, τ = 6.1 ± 0.2 milliseconds vs K1877del, τ = 5.3 ± 0.2 milliseconds; mean ± standard error of the mean, P < .009, Student t test) and a decrease in current amplitude, with averaged peak current at 6 µm, a value approximately half of wild type (P < .05; Figure 4A). The E2496ELE insertion mutant displayed increased inactivation rate compared with wild-type (9.9 ± 0.05, P < .001, Student t test). In addition, whereas the wild-type channel inactivated completely, in 77% of records from the mutant, a persistent mechanocurrent was observed, indicating incomplete channel closure (Figure 4B). Interestingly, in comparison, the K1877del mutant brings less excitation per amount of stimulus compared with WT, whereas the E2496ELE mutant brings more.
Osmotic studies
Changes in osmotic pressure, which induce a host of processes in the cell, are frequently used as a stimulus to direct mechanosensation. We tested the sensitivity of wild-type PIEZO1 expressed in HEK293 cells to different environmental osmolality. Initially, we measured changes in cell diameter in wild-type PIEZO1-expressing HEK293 cells with solutions of different tonicity: 300 mOsm, 275 mOsm, 250 mOsm, 200 mOsm, and 150 mOsm. Increases in cell diameter were observed, paralleling the degree of hypotonicity (Figure 5A). To test the mechanosensitivity of PIEZO1 to changes in environmental tonicity, a hypotonic state of 200 mOsm was chosen because it led to cell swelling without cell rupture seen at lower tonicities. We next measured MA currents, applied at 6 μm, in the whole-cell mode in uninduced and induced HEK293 cells in isotonic and hypotonic (200 mOsm) conditions. Three steps of recordings (isotonic-hypotonic-isotonic washout) were applied to each cell. There was a dramatic increase in the average peak current of MA currents in hypotonic conditions (P < .005; Figure 5B). This hypotonicity-induced increase in amplitude, like that observed in isotonic conditions, was blocked by 30 μM gadolinium chloride (Gd3+) (Figure 5C).
We next tested the sensitivity of HX-associated PIEZO1 mutants expressed in HEK293 cells to different environmental osmolality. Like wild type, the previously described M2225R mutant HX variant, had a marked increase in current amplitude after hypotonic stress. From the mutants in this report, only R2088G demonstrated a similar marked hypotonic-induced increase in current amplitude. Of the remaining mutants, the response to hypotonic stress was blunted in R2488Q and K1877del mutants whereas R2302H and E2496ELE had no response to hypotonic stress (Figure 5D).
Protein expression and membrane trafficking
Mutations in transmembrane proteins that perturb membrane trafficking and membrane protein quality have been associated with a wide variety of genetic diseases, frequently associated with mutation of lysine- or arginine-based endoplasmic reticulum (ER) retention/retrieval signals.24-28 The HX-associated arginine mutants identified are excellent candidates for an altered trafficking/quality control phenotype, as arginine-based signals may be found in a variety of locations throughout a protein, including the cytosolic NH2 terminus, intracellular loops, and the cytosolic COOH terminus of a protein.27 We examined mutants for alterations in membrane stability and trafficking in our HEK293 cell model using IF confocal microscopy.
Cells were transfected with ER-GFP, a plasmid that expresses green fluorescent protein (GFP) fused to the ER signal sequence of calreticulin and KDEL (ER retention signal), which stains the ER with minimal cellular disruption. Cells were also stained with antibody against Golgi apparatus, anti-GM130, conjugated with Alexa Fluor 488. We observed that 3 arginine mutants, R2488Q, R2302H, and R2088G, demonstrated partial intracellular retention, colocalizing with ER and Golgi markers despite immunoblotting of whole-cell extracts showing that all 3 mutant proteins were expressed at the same level as wild type (Figure 6). This indicates that despite appropriate amounts of protein synthesis of these mutants as demonstrated in total cellular extracts, the accumulation of mutant PIEZO1 protein in the ER and/or Golgi suggests a defect in vesicular to membrane transport. Interestingly, the 3 mutants that demonstrated altered membrane trafficking also demonstrated no alteration in channel inactivation.
Semiquantitative western blotting was performed using ghosts prepared from the erythrocyte membranes of affected patients. No differences in PIEZO1 expression were observed between ghosts of wild-type or mutant patients normalized against actin expression, α-spectrin expression, or both (supplemental Figure 4A-B). Artifacts introduced by western blotting including transfer efficiency of the very-high molecular PIEZO1 protein and nonlinear signal detection may preclude detection of membrane deficiency as such differences may be beyond the sensitivity of this assay. Perhaps application of sensitive proteomics, such as second-generation multiple reaction monitoring–based approaches, will provide insight into PIEZO1 quantitation in mature erythrocytes. Recently, altered PIEZO1 density on epithelial membranes has been shown to alter cellular phenotype.29 It will be interesting to determine whether erythrocyte membrane density of PIEZO1 proteins influences its function in mature erythrocytes, especially in mutant cells that may exhibit PIEZO1 deficiency.
Morphologic analyses and the E2496ELE mutant
The morphology of wild-type and HX-associated mutant PIEZO1-expressing HEK293 cell lines was examined 48 hours after doxycycline induction. Except for the E2496ELE mutant, there were no major morphologic differences between paired uninduced and induced cells. After induction, the E2496ELE mutant demonstrated cell swelling, rolling up of cell edges, and detachment from the plate.
Because there was a morphologic phenotype with the E2496ELE mutant, and because it is one of the most commonly identified HX-associated PIEZO1 mutations, we performed additional studies. In a time-course experiment with constant recording, these cells demonstrated morphological changes as early as 16 hours postinduction with swelling and rounding up of cell edges, followed by wide-scale detachment of cells from the plate by 48 hours (Figure 7A; supplemental Video 1; supplemental Figure 5). Beginning at 48 hours postinduction, live cell numbers determined by CCK8 staining dramatically decreased and mutant cells began to undergo apoptosis as determined by annexin V binding (Figure 7B).
Attempts to block this process by the addition of various inhibitors, including 4 μM Grammostola spatulata mechanotoxin (GsMTx4), 30 μM gadolinium, or 30 μM ruthenium red, yielded limited to no change in cell swelling, detachment, and apoptosis (Figure 7A-B; not shown). It is possible that this mutation leads to conformational changes in the channel and/or interrupt PIEZO1 interactions with cytoskeleton protein(s) responsible for adherence. In addition, these morphologic changes were not altered by performing similar time-course experiments in calcium-free media.
Cotransfection of wild-type, full-length PIEZO1, with enhanced GFP as a marker of transfection, into mutant cells 12 hours prior to induction did not fully rescue the apoptotic, decreased cell number phenotype (supplemental Figure 6). The number of detached cells in suspension was statistically decreased (number of total cells, P = .01; number of live cells, P = .1). However, the total number of all cells (attached and in suspension) was not statistically different (P = .1).
Discussion
Identification of mutations in PIEZO1 as the primary cause of HX has led to both an increased awareness of the disease and an increase in its diagnosis, particularly by genetic-based methodologies. Like the subjects reported here, many HX patients had been labeled with the diagnosis of “congenital anemia” until genetic diagnosis was obtained. This report demonstrates several interesting features of PIEZO1 variants and hematologic disease.
PIEZO1 variants coinherited with other congenital hemolytic anemias may alter the clinical phenotype
In the proband studied from kindred 4, the R2302H PIEZO1 mutant was coinherited with a heterozygous β-thalassemia mutant, β-globin-Cincinnati,13 predicted to produce an elongated β-chain nearly identical to β-globin Geneva. Although patients with β-globin Geneva exhibited only a chronic, mild microcytic anemia,30 our patient exhibited transfusion-dependent anemia. Her clinical severity may have been exacerbated by the PIEZO1 R2302H variant which exhibited a trafficking phenotype. A recent report described a young man with HX due to a PIEZO1 mutation whose erythrocyte dehydration and clinical severity were accentuated by coinheritance of hemoglobin C trait.31 It is not surprising that deleterious PIEZO1 mutants coinherited with other congenital anemias would worsen the clinical phenotype. Coinherited mutations would especially be predicted to lead to a more severe phenotype in inherited disorders with secondary erythrocyte dehydration, including sickle cell disease, β-thalassemia, hemoglobin C, and hereditary spherocytosis.1
Similarly, PIEZO1 variants coinherited with other congenital hemolytic anemias may ameliorate the clinical phenotype. Patient 3, who previously was described to have a deleterious mutation in the Gardos channel, KCNN4, was found to have a homozygous, in-frame deletion in PIEZO1: K1877del. This variant exhibited decreased current and increased channel kinetics, features predicted to ameliorate the dehydration phenotype. This PIEZO1 variant was identified in an Italian HX kindred with a different mutation of KCNN4: R352H.32 In that kindred, an HX patient who coinherited the K1877del PIEZO1 allele exhibited less erythrocyte dehydration than another family member who did not.
Some PIEZO1 variants are common, especially in specific ethnic groups
In northern European populations, 2 HX-associated PIEZO1 variants, the originally described R2456H mutant, and the E2496ELE found in 4 unrelated kindreds in our study, appear to be among the most common variants found in typical HX patients.6-10 Haplotype analyses reveal that the E2496ELE mutation is found on at least 4 different haplotypes.6
One PIEZO1 mutant in our study, R1943Q, was identified in an African American woman with a typical HX phenotype. This variant, classified as rs115799619, is a relatively common allele in Africans with an allele frequency of 0.02 in both 1000 Genomes and ExAc. It is African specific and there are no rs115799619 homozygotes in 1000 Genomes or ExAc, despite its frequency. The K1877 deletion is common in Europeans with an allele frequency of 0.39, whereas the allele frequency is 0.14 in Africans and 0.08 in East Asians. Like other reports, 3 of the variants in this report are novel and 1 occurred de novo. Given the large size of the PIEZO1 gene, it is not surprising that new HX-associated mutations continue to be identified, including those that occur de novo, contributing to the genetic heterogeneity seen in the HX syndromes.
Some PIEZO1 variants exhibit defective membrane trafficking
Defects in membrane trafficking of ion channels linked to hereditary hemolytic anemia have been described in band 3, the anion exchanger (SLC4A1), in patients with dominant hereditary spherocytosis.26 A series of band 3 variant alleles, many with juxtamembrane arginine mutations similar to the PIEZO1 mutants, exhibited defective folding and retention in the ER–Golgi-intermediate compartment–cis Golgi transport pathway. Frequently, misfolded mutants have abnormally long contact with ER chaperones and then are degraded. To better understand PIEZO1 trafficking, it will be important to identify PIEZO1 chaperones, as well as to determine whether PIEZO1 dimerizes or trimerizes in the ER during its synthesis and if this oligomerization is critical for its folding and membrane trafficking.26,33,34 In some dominant disorders, not only are mutant homozygous heteromeric proteins mistrafficked, but also wild-type-mutant heteromeric proteins are retained in the ER, further accentuating the clinical phenotype.
PIEZO1 and erythrocyte volume
Some of the HX-associated PIEZO1 variants tested exhibited an altered phenotype during hypotonic stress. It has been suggested that PIEZO1 plays a role in erythrocyte volume regulation, with PIEZO1-mutant HX erythrocytes gradually becoming dehydrated during their repeated cycles of travel through the microcirculation, associated with changes in oxygenation/deoxygenation.35 Genetic and physiologic studies implicate a role for PIEZO1 in volume homeostasis. Volume sensing, a poorly understood process in vertebrate cells, has been linked to stretch-activated currents induced by changes in cell volume.36 As soon as the PIEZO proteins were identified, they were candidates for cellular osmosensors.37 Physiologic studies have shown that the PIEZO1 blocker, GsMTx4, inhibits both MA currents and whole-cell regulatory volume decreases in NRK-49 cells,36,38 indicating a role for PIEZO1 in volume homeostasis.38 Recent studies demonstrate mechanical perturbations of the lipid bilayer alone are sufficient to activate PIEZO1 channels, demonstrating their innate properties as molecular force transducers.39 Piezo1-deficient murine erythrocytes exhibit overhydration, suggesting a role as a negative regulator of erythrocyte volume.40 They also demonstrate a near total lack of MA calcium influx, indicating that PIEZO1 is probably the major mechanotransducer in red blood cells. PIEZO1 activation could be mediated by transient cell swelling, a phenomenon not detected by our in vitro model. It will be exciting to tease out the contribution of PIEZO1 to volume regulation of erythrocytes as they travel through the circulation.
As shown by genome-wide association studies (GWASs), a substantial component of variability in erythrocyte hydration is genetically determined.41,42 In normal human subjects, variation in the indices of erythrocyte hydration and volume homeostasis, including hemoglobin, cell volume, and MCHC, are strongly influenced by genetic factors.43,44 Because numerous pathways regulate erythrocyte hydration, one would predict that any of the proteins participating in this process, from transporters and channels to their regulatory kinases and phosphatases and other important regulatory proteins, may serve as modifiers of erythrocyte hydration.45 A GWAS of red cell indices and related parameters was performed in 135 367 individuals.46 For MCHC, the most significant association for MCHC was a single-nucleotide polymorphism (SNP) at 16q24, rs10445033 (P < 10e-8). Using expression and bioinformatic strategies, this SNP, located in intron 1 of the PIEZO1 gene locus, was linked to PIEZO1, explaining 8% of the phenotypic variance of the MCHC trait. A recent GWAS study in Hispanics and Latinos identified a different SNP in PIEZO1 linked to MCHC.47
These studies indicate that variant PIEZO1 alleles are common, some are enriched in various ethnic groups, and some are trait and/or disease-associated. Coinheritance of modifier alleles should be considered whenever a patient with a primary or secondary erythrocyte disorder presents with an unexpectedly severe or mild clinical phenotype. Paralleling the genetic heterogeneity, mechanisms of PIEZO1 dysfunction are variable, with some yet undiscovered. Interesting observations have been made about PIEZO1 in erythrocytes, such as its role in influencing calcium and adenosine triphosphate content.40,48 The ultimate goal is understanding the precise function(s) of wild-type and mutant PIEZO1 in erythrocytes as they travel through the high-sheer-stress circulatory system and squeeze through the hypoxic capillary bed, to then understand the precise mechanism of dehydration in HX erythrocytes.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
Acknowledgments
The authors thank Mark Lessard of the Yale Cooperative Center of Excellence in Hematology (YCCEH) for technical assistance.
This work was supported in part by grants from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (RO1DK104046 and U54DK106857), the American Society of Hematology, and the Doris Duke Research Foundation.
Authorship
Contribution: E.G. designed and performed experiments and analyzed data, with contributions from E.R.S.; K.L.-G. and Y.M. designed and performed experiments; V.P.S. analyzed data; J.W., K.R., S.B.K., D.M., A.M.F., R.A.A., and T.A.K. phenotyped, diagnosed, and collected additional information on patients; E.O.G. and S.N.B. designed experiments and analyzed data; and P.G.G. designed experiments, analyzed data, and wrote the manuscript.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Patrick G. Gallagher, Yale University School of Medicine, 333 Cedar St, PO Box 208064, New Haven, CT 06520-8064; e-mail: patrick.gallagher@yale.edu.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal